Show simple item record

dc.contributor.authorKelly, Deanna L
dc.contributor.authorClaxton, Amy
dc.contributor.authorBidollari, Ilda
dc.contributor.authorDu, Yangchun
dc.date.accessioned2021-06-21T15:20:13Z
dc.date.available2021-06-21T15:20:13Z
dc.date.issued2021-05-27
dc.identifier.urihttp://hdl.handle.net/10713/16058
dc.description.abstractOne strategy to address hyperprolactinemia and associated sexual side effects in patients receiving antipsychotics is switching to an antipsychotic not associated with prolactin elevation (eg, aripiprazole). This post hoc analysis assessed prolactin concentrations and sexual side effects in an open-label prospective study of switching long-acting injectable antipsychotics from paliperidone palmitate (PP) to aripiprazole lauroxil (AL). Serum prolactin was measured throughout the study. Patient-reported sexual and endocrine side effects were assessed on the UKU Side Effect Rating Scale sexual function subscale and analyzed in study completers. Prior to starting AL treatment (screening), 49/50 (98%) patients had prolactin concentrations above the upper limit of normal (ULN; >13.13 ng/mL [males]; >26.72 ng/mL [females]). Six months after beginning AL treatment, prolactin levels were above ULN in 2/32 (6.3%) patients. Among 32 study completers, 81.3% reported sexual dysfunction in ≥1 domain at screening versus 56.3% at 6 months after starting AL treatment. Diminished sexual desire was the most common patient-reported sexual complaint at screening (46.9%); at 6 months, it was reported by 18.8%. In this post hoc analysis, the high levels of prolactin observed at screening decreased during AL treatment, and modest improvements in sexual side effects were evident in patients with schizophrenia.en_US
dc.description.urihttps://doi.org/10.1016/j.psychres.2021.114030en_US
dc.language.isoenen_US
dc.publisherElsevier B.V.en_US
dc.relation.ispartofPsychiatry Researchen_US
dc.rightsCopyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.en_US
dc.subjectAntipsychotic agentsen_US
dc.subjectDopamine D2 receptor antagonistsen_US
dc.subjectDrug side effectsen_US
dc.subjectDrug switchingen_US
dc.subjectHyperprolactinemiaen_US
dc.subjectSexual dysfunction, physiologicalen_US
dc.titleAnalysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxilen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.psychres.2021.114030
dc.identifier.pmid34118485
dc.source.volume302
dc.source.beginpage114030
dc.source.endpage
dc.source.countryIreland


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record